BR0115246A - Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso - Google Patents
Peptìdeos imunomoduladores derivados de proteìnas de choque e seu usoInfo
- Publication number
- BR0115246A BR0115246A BR0115246-7A BR0115246A BR0115246A BR 0115246 A BR0115246 A BR 0115246A BR 0115246 A BR0115246 A BR 0115246A BR 0115246 A BR0115246 A BR 0115246A
- Authority
- BR
- Brazil
- Prior art keywords
- immune
- modulating
- inflammation
- homologous
- shock protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000035939 shock Effects 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108020000946 Bacterial DNA Proteins 0.000 abstract 1
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008102 immune modulation Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"PEPTìDEOS IMUNOMODULADORES DERIVADOS DE PROTEìNAS DE CHOQUE TéRMICO E SEU USO". A presente invenção refere-se a um método de modulação de uma resposta imune em um indivíduo. A invenção baseia-se na descoberta de que uma estratégia terapêutica eficaz para melhorar os sintomas relacionados com inflamação de uma doença imune-mediada, tal como artrite, pode ser alcançada mediante a modulação da resposta imune fundamental propriamente dita, em vez de simplesmente se voltar para a inflamação resultante. Esta estratégia pode ser usada para regular a resposta inflamatória e é aplicável a uma variedade de contextos em que a modulação imune é desejada, tal como tolerância da mucosa, vacinação de DNA, indução de energia, imunização ativa, e modulação ex vivo de células T específicas do antígeno. Em uma modalidade, o método compreende administrar ao indivíduo um peptídeo de dnaJ bacteriana ou uma isoforma humana homóloga ou não homóloga deste.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24518100P | 2000-11-01 | 2000-11-01 | |
| PCT/US2001/045344 WO2002036611A2 (en) | 2000-11-01 | 2001-10-31 | Immunomodulatory peptides derived from heat shock proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0115246A true BR0115246A (pt) | 2005-04-26 |
Family
ID=22925623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0115246-7A BR0115246A (pt) | 2000-11-01 | 2001-10-31 | Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7301005B2 (pt) |
| EP (1) | EP1355923B1 (pt) |
| JP (1) | JP4264257B2 (pt) |
| KR (1) | KR20030055295A (pt) |
| CN (1) | CN1481390B (pt) |
| AT (1) | ATE548376T1 (pt) |
| AU (1) | AU2002220038A1 (pt) |
| BR (1) | BR0115246A (pt) |
| CA (1) | CA2427572A1 (pt) |
| EA (1) | EA005821B1 (pt) |
| IL (1) | IL155610A0 (pt) |
| MX (1) | MXPA03003901A (pt) |
| WO (1) | WO2002036611A2 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006052773A2 (en) * | 2004-11-07 | 2006-05-18 | Androclus Therapeutics Inc. | Treatments for demyelinating immune mediated diseases |
| US20080089843A1 (en) * | 2006-05-25 | 2008-04-17 | Reddy's Laboratories, Inc. | Use of biomarkers of inflammation as indicators of drug efficacy |
| AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
| US8742068B2 (en) | 2007-07-06 | 2014-06-03 | Universiteit Utrecht Holding B.V. | Treatment and prevention of inflammatory diseases and autoimmune diseases |
| RU2722357C2 (ru) * | 2010-07-26 | 2020-05-29 | Кью Байолоджикс Инк. | Иммуногенные противовоспалительные композиции |
| RU2483746C1 (ru) * | 2012-05-17 | 2013-06-10 | Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Средство для антиагрегатной, антивоспалительной и цитопротекторной терапии |
| KR101632948B1 (ko) * | 2014-05-13 | 2016-06-27 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
| KR102592673B1 (ko) | 2016-05-25 | 2023-10-24 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역요법의 방법 |
| WO2019155415A1 (en) * | 2018-02-09 | 2019-08-15 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Immunomodulating and immunostimulating polypeptides for drug-delivery |
| GB201807831D0 (en) * | 2018-05-15 | 2018-06-27 | Univ College Cardiff Consultants Ltd | Cancer Vaccine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732757A (en) | 1978-02-06 | 1988-03-22 | Stolle Research And Development Corporation | Prevention and treatment of rheumatoid arthritis |
| US4683295A (en) | 1984-05-24 | 1987-07-28 | Scripps Clinic And Research Foundation | Method for the preparation of anti-receptor antibodies |
| US4654419A (en) | 1984-08-08 | 1987-03-31 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen |
| US5116725A (en) | 1984-08-08 | 1992-05-26 | Scripps Clinic And Research Foundation | Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| WO1990014835A1 (en) | 1989-05-31 | 1990-12-13 | Scripps Clinic And Research Foundation | Method to treat rheumatoid arthritis |
| CA2063271A1 (en) * | 1989-07-14 | 1991-01-15 | Subramonia Pillai | Cytokine and hormone carriers for conjugate vaccines |
| US5891435A (en) | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5773570A (en) * | 1994-05-20 | 1998-06-30 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| JPH10500679A (ja) | 1994-05-20 | 1998-01-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 慢性関節リウマチを治療するための方法および試薬 |
| US5993803A (en) | 1996-08-30 | 1999-11-30 | Yeda Research And Development Co., Ltd. | Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity |
| DE19702065C1 (de) * | 1997-01-22 | 1998-05-20 | Kurzik Dumke Ursula Dr | Polyklonaler Antikörper zum Nachweis des tumorassoziierten Antigens hTid |
| US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US5992567A (en) | 1999-01-29 | 1999-11-30 | Chiu; Ping-Jan | Foldable frame |
-
2001
- 2001-10-31 CA CA002427572A patent/CA2427572A1/en not_active Abandoned
- 2001-10-31 US US10/001,938 patent/US7301005B2/en not_active Expired - Fee Related
- 2001-10-31 MX MXPA03003901A patent/MXPA03003901A/es not_active Application Discontinuation
- 2001-10-31 AT AT01992716T patent/ATE548376T1/de active
- 2001-10-31 WO PCT/US2001/045344 patent/WO2002036611A2/en active Application Filing
- 2001-10-31 AU AU2002220038A patent/AU2002220038A1/en not_active Abandoned
- 2001-10-31 CN CN018207642A patent/CN1481390B/zh not_active Expired - Fee Related
- 2001-10-31 JP JP2002539369A patent/JP4264257B2/ja not_active Expired - Fee Related
- 2001-10-31 KR KR10-2003-7006086A patent/KR20030055295A/ko not_active Application Discontinuation
- 2001-10-31 IL IL15561001A patent/IL155610A0/xx unknown
- 2001-10-31 EA EA200300438A patent/EA005821B1/ru not_active IP Right Cessation
- 2001-10-31 EP EP01992716A patent/EP1355923B1/en not_active Expired - Lifetime
- 2001-10-31 BR BR0115246-7A patent/BR0115246A/pt not_active IP Right Cessation
-
2007
- 2007-11-12 US US11/938,762 patent/US20080187550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1481390A (zh) | 2004-03-10 |
| EA200300438A1 (ru) | 2003-12-25 |
| WO2002036611A3 (en) | 2003-08-21 |
| US20030031679A1 (en) | 2003-02-13 |
| JP2004537496A (ja) | 2004-12-16 |
| IL155610A0 (en) | 2003-11-23 |
| WO2002036611A2 (en) | 2002-05-10 |
| EA005821B1 (ru) | 2005-06-30 |
| KR20030055295A (ko) | 2003-07-02 |
| CN1481390B (zh) | 2010-12-22 |
| MXPA03003901A (es) | 2004-09-10 |
| EP1355923B1 (en) | 2012-03-07 |
| AU2002220038A1 (en) | 2002-05-15 |
| EP1355923A2 (en) | 2003-10-29 |
| ATE548376T1 (de) | 2012-03-15 |
| JP4264257B2 (ja) | 2009-05-13 |
| US20080187550A1 (en) | 2008-08-07 |
| US7301005B2 (en) | 2007-11-27 |
| CA2427572A1 (en) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0115246A (pt) | Peptìdeos imunomoduladores derivados de proteìnas de choque e seu uso | |
| BR0211474A (pt) | Uso de tat de hiv-1 biologicamente ativa, fragmentos ou derivadas desta, para atingir e/ou ativar células apresentadoras de antìgeno, e/ou para disponibilizar moléculas carga para vacinação e/ou tratamento preventivo ou terapêutico de outras doenças | |
| Sambhara et al. | Immunosenescence and influenza vaccine efficacy | |
| BR0206689A (pt) | Combinação de probióticos, e, uso desta | |
| Isaka et al. | Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant | |
| Seledtsov et al. | A balance between tissue-destructive and tissue-protective immunities: a role of toll-like receptors in regulation of adaptive immunity | |
| BR9907228A (pt) | Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória | |
| Hochreiter et al. | Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen | |
| ES2753142T3 (es) | Vacuna y métodos para reducir una infección por Campylobacter | |
| HRP20170193T4 (hr) | Izolirani polipeptid iz proteina toksina a i toksina b iz c.difficile i njegove uporabe | |
| BR9809914A (pt) | Genes de moracella receptores de lactoferrina | |
| Martínez-Gómez et al. | The intraperitoneal inoculation of Lactobacillus casei in mice induces total protection against Trichinella spiralis infection at low challenge doses | |
| Pacífico et al. | Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine | |
| ATE337791T1 (de) | Das einbringen von nukleinsäuremolekülen in schleimhautgewebe | |
| BR0206347A (pt) | Conjugados de compostos de macrolìdeo especìficos a células imunes com compostos antiinflamatórios para objetivação celular aperfeiçoada de terapia antiinflamatória | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| ATE332379T1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| Kumar et al. | Induction of immunostimulatory cytokine genes expression in human PBMCs by a novel semiquinone glucoside derivative (SQGD) isolated from a Bacillus sp. INM-1 | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| Rezaei et al. | In silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with chitosan nanoparticles against uropathogenic Escherichia coli | |
| Rojas-Torres et al. | Importancia del déficit selectivo de inmunoglobulina A | |
| De Magistris | Zonula occludens toxin as a new promising adjuvant for mucosal vaccines | |
| Slater et al. | Murine B-cell and T-cell epitopes of the allergen Hev b 5 from natural rubber latex | |
| Biregani et al. | Allergen specific immunotherapy with plasmid DNA encoding OVA-immunodominant T cell epitope fused to Tregitope in a murine model of allergy | |
| BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |